Adaptive Shield, a CrowdStrike Company, Recognized as Frost Radar™ Leader in SaaS Security Posture Management

Adaptive Shield Named Leader in SaaS Security Posture Management CrowdStrike’s Adaptive Shield Recognized by Frost Radar™ AUSTIN, Texas–(BUSINESS WIRE)–CrowdStrike (NASDAQ: CRWD) today announced that Adaptive Shield, a CrowdStrike company, has been named the Leader in the 2024 Frost Radar™: SaaS Security Posture Management (SSPM), earning the highest and farthest-right position among all evaluated vendors. With…

Read More

Get Ready to Celebrate: Ethereum Skyrockets to $4k, Pepe Breaks Records, and Coinbase Welcomes MOG while Upbit Embraces MOVE!

Exciting Times in the Cryptocurrency Market! What a rollercoaster ride it has been for Ethereum, PEPE, MOG, and MOVE! Earlier today, Ethereum’s price briefly hit $4,000 before pulling back following strong institutional interest and whale activity. This is both exhilarating and nerve-wracking for crypto investors. The volatile nature of the market keeps us on our…

Read More

Revolutionizing Cancer Treatment: Poseida Therapeutics’ Promising Progress at ASH Annual Meeting

Additional Data from Poseida Therapeutics Shows Promising Results in Multiple Myeloma Treatment Optimized Lymphodepletion Arm Demonstrates Consistent Cellular Expansion New profiling of patient responses from Poseida Therapeutics’ optimized lymphodepletion arm (Arm C) has shown consistent expansion and persistence of P-BCMA-ALLO1 cellular therapy across different subgroups. This data is a promising sign for the ongoing Phase…

Read More

Discover the Power of Aptose: Promising Clinical Data Showcased at 2024 ASH Annual Meeting for Tuspetinib Triple Drug Therapy in Newly Diagnosed AML Patients

Discover the Power of Aptose: Promising Clinical Data Showcased at 2024 ASH Annual Meeting for Tuspetinib Triple Drug Therapy in Newly Diagnosed AML Patients Description: TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. Sites. TUS and TUS+VEN Broadly Active Across AML Populations, with Favorable Safety. TUS-based therapies are active in…

Read More